Veracyte (NasdaqGM:VCYT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsJohn Leite - Global Chief Commercial OfficerKyle Mikson - Managing DirectorMarc Stapley - CEOPhillip Febbo - Chief Scientific Officer and Chief Medical OfficerRebecca Chambers - CFOShayla Gorman - Senior Director of Investor RelationsConference Call ParticipantsAndrew Brackmann - AnalystBill Bonello - Senior Research AnalystDoug Schenkel - Managing Director and Senior Research AnalystKeith Hinton - Senior Analys ...

Veracyte (NasdaqGM:VCYT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsJohn Leite - Global Chief Commercial OfficerKyle Mikson - Managing DirectorMarc Stapley - CEOPhillip Febbo - Chief Scientific Officer and Chief Medical OfficerRebecca Chambers - CFOShayla Gorman - Senior Director of Investor RelationsConference Call ParticipantsAndrew Brackmann - AnalystBill Bonello - Senior Research AnalystDoug Schenkel - Managing Director and Senior Research AnalystKeith Hinton - Senior Analys ...

Core Insights - Veracyte, Inc. is expected to report quarterly earnings on February 25, 2026, with an anticipated EPS of $0.41 and revenue of approximately $135.8 million, driven by its genomic diagnostics tests, Decipher and Afirma [1][5] Financial Performance - In the previous quarter, Veracyte's adjusted EPS was $0.51, exceeding the Zacks Consensus Estimate by 59.38%, and the company has consistently surpassed earnings estimates over the last four quarters with an average surprise of 45.12% [2] - The upcoming Q4 EPS estimate reflects a 13.9% increase from the previous year, with earnings estimates revised upwards by 2% ahead of the announcement [2] Valuation Metrics - Veracyte's financial metrics indicate a high valuation, with a P/E ratio of approximately 94.73, suggesting investors are willing to pay a premium for its earnings [3][5] - The price-to-sales ratio is about 5.82, indicating that investors are paying over five times the company's sales per share [3] - The enterprise value to sales ratio is around 5.27, and the enterprise value to operating cash flow ratio is approximately 24.10 [3] Financial Health - The company's earnings yield is about 1.06%, and it maintains a low debt-to-equity ratio of 0.03, indicating minimal reliance on debt financing [4] - Veracyte has a strong current ratio of 6.23, suggesting robust liquidity and the ability to cover short-term liabilities [4]

Registration No. 333- As filed with the Securities and Exchange Commission on February 25, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRINITY BIOTECH PLC (Exact name of registrant as specified in its charter) (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Ireland 2835 Not Applicable IDA Business Par ...

- Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company’s ambitions to expand its commercialisation activities and advance its innovation agenda DUBLIN, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has entered into a $25 million Standby Equity Purchase Agreeme ...

Core Insights - VolitionRx Limited has made significant clinical and commercial progress, highlighting licensing momentum and advancements in various diagnostic technologies [1][2] Group 1: Licensing and Commercialization - The company is in active discussions with approximately 10 global diagnostic leaders for licensing agreements [1][2] - Anticipated announcements of additional agreements during 2026 as negotiations progress [2] Group 2: Clinical Developments - The Nu.Q® NETs assay is included in a $7.3 million government-backed DETECSEPS program in France for early sepsis detection [1] - A reimbursement submission for lung cancer testing in France is underway, with routine clinical use expected by Q4 2026 [1] - New clinical utility of the Nu.Q® NETs assay has been demonstrated for managing Hidradenitis Suppurativa, a disease affecting about 1% of the global population [1] Group 3: Market Opportunities - The Capture-Seq™ platform presents a $23 billion annualized opportunity in cancer detection [1][2] - The total addressable market for Nu.Q® NETs in sepsis and chronic conditions is estimated at $3.8 billion [2] - The Nu.Q® Vet (Canine/Feline) market is projected to exceed $1 billion, with the canine test already commercially available [2] Group 4: Veterinary Breakthroughs - The Nu.Q® Vet Feline assay achieved 100% specificity in detecting feline lymphoma, marking a significant advancement in veterinary diagnostics [1] - This breakthrough is expected to unlock a $5 million milestone payment upon publication in a peer-reviewed journal [1]

RaDaR ST uses patient-specific, tumor-informed panels to detect trace amounts of tumor DNA in blood, often before recurrence is visible on imaging. The assay combines whole-exome sequencing with advanced bioinformatics to track up to 48 tumor-specific variants with a limit of detection at 95% probability (LOD95) of 11 ppm, offering high sensitivity and specificity.* FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision m ...

CareDx (NasdaqGM:CDNA) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAndrew Cooper - VP of Equity ResearchBrandon Couillard - Managing DirectorCaroline Corner - Director of Investor RelationsJohn Hanna - President and CEOKeith Kennedy - COONathan Smith - CFOTycho Peterson - Managing DirectorConference Call ParticipantsAndrew Brackmann - Equity Research AnalystBill Bonello - Senior Research AnalystEduardo Martinez - Equity Research AnalystMason Carrico - Research AnalystVivian Cerva ...

Tempus AI, Inc. Investor Presentation Q4 2025 and Full Year 2025 FEBRUARY 2026 Disclaimer This presentation contains forward-looking statements that reflect Tempus AI, Inc.'s (the "Company" or "Tempus") current expectations and projections with respect to, among other things, its financial condition, results of operations, plans, objectives, future performance and business. Forward-looking statements include all statements that are not historical facts. Such forward-looking statements are subject to various ...

Mainz Biomed to Present Industry Leading Results: 100% Sensitivity and 95% SpecificityBERKELEY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the renowned Digestive Disease Week (DDW) 2026 in Chicago, Illinois. At the conference the Company will present its poster titled “BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA A ...